Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of 1,4-Benzodioxane Derivatives as F-18 PET Radiotracers for Alpha-2C Adrenergic Receptors and Their Preclinical Evaluations

Award Number: R21AG083663
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Development of 1,4-Benzodioxane Derivatives as F-18 PET Radiotracers for Alpha-2C Adrenergic Receptors and Their Preclinical Evaluations - PROJECT SUMMARY Millions of middle-aged and seniors in the United States maintain their blood pressure and prevent cardiovascular emergencies by taking - and -blockers daily. The total global market grew to $20 B for these drugs in 2017. These two important drug classes commonly target adrenergic receptors (ARs) that execute critical physiological functions such as respiration, digestion, circulation, emotion, memory, and cognition mediated by norepinephrine (NE). Many - and -blockers bind nonspecifically to ARs and do not only produce pharmaceutical effects but also accompany critical side effects. Therefore, subtype-selective AR agonists and antagonists can achieve the desired goals without inducing the side effects. Such a request for the two drug classes has been largely ignored. Among the nine subtypes of ARs, the biologic properties of 2C-ARs drew interest in the pharmaceutical industry. The presynaptic 2C-ARs regulate the release of NE, dopamine, and serotonin to the synapse. The brain 2C-ARs mainly concentrate in the limbic regions, such as the striatum and hippocampus. Taking these properties together, the 2C-ARs can selectively control the neurotransmitter levels in the limbic regions without affecting the levels in the prefrontal regions. Alzheimer’s disease (AD) features neuronal loss in the hippocampus, where 2C-ARs are abundant and might be changed by the noradrenergic neurons projected from locus coeruleus, the first brain system affected by AD. In substance use disorder (SUD), activation of the 2C-ARs can reduce the neuronal hyperactivity in the limbic regions without affecting the brain circuit toward the prefrontal cortex, which inhibits the instinctive behavior toward brain stimulants and facilitates rational judgment against them. Therefore, 2C-ARs can be a good drug target, and their positron emission tomography (PET) radiotracer can monitor their biological properties under various disease conditions. [11C]ORM13070 is an important milestone because this is the first successful subtype-specific AR radiotracer among their nine subtypes. However, its pharmacokinetic properties and specificities have to be improved. The current project will develop the first fluorine-18 (F-18) 2C-AR radiotracers and evaluate them by comparing their properties with [11C]ORM13070. We designed various 1,4-benzodioxane derivatives based on ORM13070. The current strategy based on the existing molecular frame reduces the risk of failure and increases the success of the development with short-term funding. The experience will eventually lead to future development based on a new molecular framework. The current project selected seven candidate compounds using a computer-aided docking model study. These compounds will be synthesized, and receptor-binding assays will further select the compounds. After the target radiotracers are prepared, preclinical PET imaging studies will evaluate them. The PET imaging data will also be validated by autoradiography and immunohistology. The successful radiotracer can be patented for the application of diagnosis because Orion Pharma claimed them only as drugs, and will be applied to SUD and AD preclinical imaging research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = -$427,915 )
2027	2025	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Aging Research	000	2	10/15/2026	NON-COMPETING CONTINUATION	-$427,915
														Subtotal = -$427,915

Issue Date FY: 2025 ( Subtotal = $194,513 )
2025	2025	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Aging Research	000	2	7/16/2025	NON-COMPETING CONTINUATION	$194,513
														Subtotal = $194,513

Issue Date FY: 2024 ( Subtotal = $233,402 )
2024	2024	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Aging Research	000	1	9/11/2024	NEW	$233,402
														Subtotal = $233,402

Grand Total All Awards = $0

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of 1,4-Benzodioxane Derivatives as F-18 PET Radiotracers for Alpha-2C Adrenergic Receptors and Their Preclinical Evaluations

Award Number: R21AG083663

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer